Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Smoking is a well – known risk factor of many diseases. It influences the efficacy and safety of drug treatment by affecting the course of different physiological processes and modifying the metabolism of drugs. The number of researches showed decrease in efficacy of some cardiovascular drugs in smokers.

Aim. To compare efficacy and safety of selective and non-selective beta–adrenoceptor blockers in smokers and nonsmokers with chronic ischemic disease.

Material and Methods. Antianginal efficacy of drugs in patients of both groups was evaluated by burden tests on treadmill, effective doses of bisoprolol and propranolol were adjusted.

Results. The result shows that smokers two times more often need prescription of double doses of drugs. Depressed antianginal activity of both beta-adrenoceptor blockers, especially of non-selective propranolol, in smokers was revealed. When evaluating the parameters of spirography, it was found that non-selective beta-adrenoceptor blocker propranol statistically significant decreases figures of bronchial passage, irrespective of the status of smoking. Moreover, with propranol treatment, bigger number of side effects is registered in both groups, demonstrating 30% more in smok￾ers compared to nonsmokers.

Conclusion. Smoking attenuates efficacy and safety of beta-blockers, especially these of non-selective ones.

About the Author

J. V. Lukina
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation
Russian Federation

Preventive Pharmacology Department


1. Гафаров В.В., Пак В.А., Гагулин И.В., Гафарова А.В. Эпидемиология и профилактика хронических неинфекционных заболеваний в течение 2-х десятилетий и в период социально-экономического кризиса в Россию Новосибирск, 2000, 284с.

2. Демографический ежегодник России. Статистический сборник. М., 2001, 403 с.

3. Кузнецов Г.П., Перепелкина Н.Б. Влияние курения на различные гемодинамические показатели у пациентов со стенокардией напряжения и здоровых лиц Кардиология, 1982, 22, №11, стр.41-4.

4. Профилактическая фармакология в кардиологии (под ред. В.И.Метелицы; Р.Г.Оганова) – М., «Медицина» 1988: 23-36

5. Сахарова Г.М., Чучалин А.Г. Лечение табачной зависимости РМЖ, 2001, 9(5):168-173

6. Хроническая обструктивная болезнь легких. Клинические рекомендации. М., 2004.

7. Хронические обструктивные болезни легких. Федеральная программа. МЗ РФ. Всероссийское научное общество пульмонологов. М. 1999: 3-15.

8. Шальнова С.А. Факторы риска сердечно-сосудистых заболеваний и показатели ожидаемой продолжительности жизни населения России.// Автореф. дис. докт.мед.наук – М. – 1999, 46с.

9. Шальнова С.А., Деев А.Д., Оганов Р.Г. Распространенность курения в России. Результаты обследования национальной представительной выборки населения Профилактика заболеваний и укрепление здоровья , 1998, №3, стр.9-12.

10. Bang LE, Buttenschon L., Kristensen KS, Svendsen TL. Do we undertreat hypertensive smokers? A comparison between smoking and non-smoking hypertensives. Circulation 1994, 90 (1): 248-53

11. Barry J., Mead K., Nabel E.G. Effect of smoking on the activity of ischemic heart disease. JAMA, 1989, 261(3): 398-402.

12. Berkan T., Ustunes L., Kerry Z. et al. The effect of a single treatment with cigarette smoke on the blood levels and hemodynamic effects of propranolol in rats Eur. J. Drug Metab. Pharmacokinet, 1989, 14(3): 221-8.

13. De Cesaris R, Raniery G, Filitti V et al. Cardiovascular effects of cigarette smoking. Br J Clin Pharmacol, 1987, 24 (2):173-8

14. Fox K.M. Smoking, catecholamines and the ischemic myocardium. Postgrad. Med, 1988, 29(spec. no): 148-151.

15. Heyden S, Schneider KA, Fodor JG. Smoking habits and antihypertensive treatment. Nephron, 1987, 47, Suppl 1: 99-103.

16. Hung J., Lam J.Y.T., Lacoste L., Letchakowski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.

17. Kochar MS, Bindra RS The additive effects of smoking and hypertension. More reasons to help your patients kick the habit. Poostgrad Med, 1996, 100(5), 147-154.

18. Kotamaki M, Manninen V, Laustiola KE. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur J Clin Pharmacol, 1993, 44(1): 13-7.

19. Matsuka N, Furuno K, Eto K et al., Effects of cigarette smoke inhalation on plasma diltiazem levels in rats, Methods Find Exp Clin Pharmacol, 1997, 19(3): 173-9.

20. Neunteufl T., Heher S., Koster K. et al. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J. Am. Coll. Cardiol. 2002; 39: 251-6.

21. Trap-Jensen J, Carlsen JE, Svendsen TL, Christensen NJ. Cardiovascular and adrenergic effects of cigarette smoking during immediate non-selective and non-selective beta adrenoreceptor blockade in humans. Eur J Clin Invest 1979, 9(3): 181-3.

22. Walle T., Walle U.K., Coward T.D. et al. Selective induction of propranolol metabolism by smoking: additional affects on renal clearance of metabolites. J Pharmacol Exp Ther, 1987, 241(3): 928-33.

23. Zhu B., Parmley W.W. Hemodynamic and vascular effect of active and passive smoking. Am. Heart J. 1995; 130: 1270-5.

24. Лукина Ю.В., Марцевич С.Ю., Кутишенко Н.П., Шальнова С.А. Подбор эффективных доз селективных и неселективных бета-адреноблокаторов у курящих и некурящих больных стабиль- ной стенокардией напряжения. Кардиоваскулярная терапия и профилактика 2004; 2: 43-8.

25. Лукина Ю.В., Марцевич С.Ю., Кутишенко Н.П. и др. Изменение показателей функции внешнего дыхания при лечении бета-адреноблокаторами у курящих и некурящих больных со стабильной стенокардией напряжения. Российский кардиологический журнал 2004; 2: 41-4.

For citation:

Lukina J.V. DRUGS AND SMOKING. Rational Pharmacotherapy in Cardiology. 2005;1(1):31-36. (In Russ.)

Views: 530

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)